Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fourth-Generation CAR-T in Hematologic Malignancies
NCT06758713Phase 1Recruiting
- Sponsor
- The Third Affiliated Hospital of Southern Medical University
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Fourth-Generation CAR-T in multiple myeloma (MM), B cell lymphoma and hematologic malignancy (4 arms), sponsored by The Third Affiliated Hospital of Southern Medical University. Primary endpoints: Number of patients with dose-limiting toxicity at 30 days, Maximum Tolerated Dose at 30 days and 3 more. Started Jan 2025; status: recruiting.
02
Drugs
Fourth-Generation CAR-T
03
Conditions
multiple myeloma (MM)B cell lymphomahematologic malignancy
Beyond the preview
Go deeper on NCT06758713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06758713.